-

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at:

https://jpmorgan.metameetings.net/events/healthcare25/sessions/58328-organon/webcast?gpu_only=true&kiosk=true

About Organon

Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers more than 60 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon’s scale and agile presence in fast growing international markets.

Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.

Contacts

Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Industry:

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB
Release Summary
Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th
Release Versions
English

Contacts

Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Social Media Profiles
Organon Facebook
Organon Instagram
Organon LinkedIn
Organon Twitter
More News From Organon & Co.

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will...

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Dermatology to present new Phase 3 analysis of VTAMA eczema data at the Society for Pediatric Dermatology annual meeting on July 23, 2026....

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA...
Back to Newsroom